CA-ADVA
24.1.2023 18:01:38 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Brandywine Communications is using its OSA 5422 grandmaster clock to deliver a robust and feature-rich M-Code timing solution for use cases such as US Department of Defense applications. The new edge synchronization offering addresses the key requirements of military networks by providing enhanced positioning, navigation and timing (PNT) capabilities and improved resilience. Built on Oscilloquartz’s versatile timing technology with integrated M-Code capabilities, the solution is ideal for the most demanding military edge applications. It supports 1Gbit/s and 10Gbit/s interfaces, provides innovative GNSS assurance capabilities as well as backup through Oscilloquartz’s assured PNT (aPNT+™) technology, and meets the most stringent timing demands in an operationally efficient and cost-effective way.
“Our M-Code edge timing offering will be a game-changer for defense applications. Powered by ADVA’s OSA 5422 grandmaster clock, it meets the most urgent needs of military networks that require precise and reliable PNT information and delivers new levels of reliability and security. One key feature of the OSA 5422 is its long holdover and PTP backup, which enables it to maintain accurate timing even in the event of M-Code disruption. This is critical for pressurized defense networks that need to operate in a variety of difficult environments,” said Allen Ronk, president of Brandywine Communications. “Our solution features multi-source backup capabilities to ensure that M-Code outages do not disrupt synchronization. It also provides sync assurance capabilities that continually monitor the performance of the timing system and take immediate corrective action when needed.”
M-Code is an encrypted GPS signal used exclusively by the US military in defense applications that require precise and reliable synchronization. Resistant to jamming and spoofing, M-Code is an invaluable asset for defense organizations operating in challenging conditions. ADVA’s OSA 5422 grandmaster clock is now integrated with a highly reliable M-Code receiver that meets stringent frequency and phase synchronization needs and offers the best holdover performance of any edge device on the market. Also equipped with multi-band, multi-constellation GNSS receivers for when M-Code is not available, the device offers support for legacy interfaces such as BITS and IRIG, and features eight field-upgradeable 10Gbit/s ports and 1Gbit/s interfaces. The OSA 5422 is also environmentally hardened with hot-swappable modules and power supplies for easy field upgrades.
“As military applications demand increasingly precise and reliable PNT capabilities, the need for secure, jamming- and spoofing-resistant M-Code technology becomes ever more pressing. With its long holdover, multi-source backup capabilities, sync assurance capabilities, and other advanced features, our OSA 5422 is perfectly positioned to meet this demand,” commented Gil Biran, GM of Oscilloquartz, ADVA. “We’re excited to be working with Brandywine Communications as our strategic partner and to be bringing our innovation to defense applications that rely on precise and reliable PNT in the US and elsewhere. The market for military GPS receivers with M-Code capabilities is growing, as defense organizations seek to enhance their PNT capabilities and improve resilience. Together, we’re helping empower a whole new section of customers to benefit from the industry’s most agile synchronization toolkit.”
ADVA’s Oscilloquartz aPNT+™ and M-Code technology is being showcased at the Precise Time and Time Interval Systems and Applications Meeting (PTTI 2023) in Long Beach, California, from January 23 to 26. Attendees can visit the Oscilloquartz team at Brandywine Communications’ booth to learn about the platform’s ability to provide resilient and assured PNT services for military applications in line with the Department of Defense’s latest zero-trust strategy, and how the OSA 5422 supports both time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS).
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005723/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom